Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Receivables - Accured (2022 - 2025)

Historic Receivables - Accured for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $2.2 million.

  • Zentalis Pharmaceuticals' Receivables - Accured fell 3482.6% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 3482.6%. This contributed to the annual value of $2.9 million for FY2024, which is 1180.7% down from last year.
  • As of Q3 2025, Zentalis Pharmaceuticals' Receivables - Accured stood at $2.2 million, which was down 3482.6% from $2.5 million recorded in Q2 2025.
  • Zentalis Pharmaceuticals' 5-year Receivables - Accured high stood at $3.3 million for Q4 2023, and its period low was $266000.0 during Q1 2022.
  • Moreover, its 4-year median value for Receivables - Accured was $2.2 million (2025), whereas its average is $1.9 million.
  • In the last 5 years, Zentalis Pharmaceuticals' Receivables - Accured skyrocketed by 71948.05% in 2024 and then tumbled by 3482.6% in 2025.
  • Quarter analysis of 4 years shows Zentalis Pharmaceuticals' Receivables - Accured stood at $508000.0 in 2022, then soared by 556.89% to $3.3 million in 2023, then dropped by 11.81% to $2.9 million in 2024, then decreased by 26.81% to $2.2 million in 2025.
  • Its Receivables - Accured stands at $2.2 million for Q3 2025, versus $2.5 million for Q2 2025 and $2.7 million for Q1 2025.